Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer

A single arm study: Apatinib plus paclitaxel as the reverses treatment in advanced gastric cancer which paclitaxel-resistant.

Study Overview

• Status: Unknown
• Conditions: Malignant Neoplasm of Stomach Stage II
• Intervention / Treatment: Drug: Apatinib; Drug: Paclitaxel-based chemotherapeutic regimens

Detailed Description

This trial investigated the efficacy and safety of apatinib plus paclitaxel, as a treatment option for patients with advanced gastric cancer which paclitaxel-resistant.

• Study Type: Interventional
• Enrollment (Actual): 20
• Phase: Phase 2

Contacts and Locations

Study Locations

• China
  • Fujian
    • Fuzhou, Fujian, China, 350014
      • Rongbo Lin

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Age: more than 18 years old;
2. Histologically confirmed advanced or metastatic adenocarcinoma of gastric cancer(AGC) , including adenocarcinoma of the gastroesophageal junction;
3. At least one measurable and evaluable disease based on response evaluation criteria in solid tumors (RECIST v1.1);
4. The patient with Prior Paclitaxel-Resistant;
5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2;
6. An expected survival of ≥ 3 months;
7. Duration from the last therapy is more than 6 weeks for nitroso or mitomycin, More than 4 weeks for other cytotoxic agents, operation or radiotherapy;

8. Major organ function has to meet the following criteria; (1) For results of blood routine test:

   1. Hemoglobin (HB) ≥ 80g / L,
   2. ANC ≥ 1.5 × 109 / L,
   3. PLT ≥ 75 × 109 / L, (2) For results of biochemical tests:
   1. BLT ≤ 1.25 times the upper limit of normal (ULN),
   2. ALT and AST ≤ 2.5 × ULN, liver metastases, if any, the ALT and AST≤ 5 × ULN,
   3. Serum Cr≤1ULN, Endogenous creatinine clearance rate >50ml/min;
9. Pregnancy test (serum or urine) has to be performed for woman of childbearing age within 7 days before enrolment and the test result must be negative. They shall take appropriate methods for contraception during the study until the 8th week post the last administration of study drug. For men, (previous surgical sterilization accepted), shall agree to take appropriate methods of contraception during the study until the 8th week post the last administration of study drug;
10. Patient has to voluntarily join the study and sign the Informed Consent Form for the study.

Exclusion Criteria:

1. History of other malignancies except cured basal cell carcinoma of skin and carcinoma insitu of uterine cervix;
2. Confirmed that apatinib and/or its accessories allergy;
3. Subjects with poor-controlled arterial hypertension (systolic blood pressure> 140 mmHg and diastolic blood pressure > 90 mm Hg) despite standard medical management;
4. Serious cardiovascular disease: Ⅱ-level myocardial ischemia or myocardial infarction, arrhythmia (including QT interval prolongation, for man ≥ 450 ms, for woman ≥ 470 ms); III ~ IV level cardiac function insufficiency, or echocardiography showed that left ventricular ejection fraction (LVEF < 50%);
5. Patients with positive urinary protein (urine protein detection of 2 or more, or 24 hour urine protein >1.0g);
6. Factors that could have an effect on oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction);
7. Subjects with high gastrointestinal bleeding risk, including the following conditions: local active ulcer lesions with positive fecal occult blood test (++); history of black stool, or vomiting blood in the past 2 months;unresected primary lesion in stomach with positive fecal occult blood test (+), ulcerated gastric carcinoma with massive alimentary tract bleeding risk judged by PIs based on gastric endoscopy result;
8. Abnormal Coagulation (INR>1.5、APTT>1.5 UNL), with tendency of bleed;
9. With psychotropic drug abuse history and can't get rid or with mental disorder patients;
10. Less than 4 weeks from the last clinical trial;
11. According to the researcher's judgment, with other serious diseases which harm to patient safety or affect patients complete the study;
12. Evidence of central nervous system(CNS) metastasis;
13. Pregnant or lactating women;
14. Other conditions regimented at investigators' discretion.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Experimental: Apatinib plus chemotherapy

Drug: Apatinib; Apatinib (850 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.; Drug: Paclitaxel-based chemotherapeutic regimens; Paclitaxel-based chemotherapeutic regimens including: The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.; The PF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.; Paclitaxel 80mg/m2 d1，d8，d15，repeating the cycle every 28 days; other paclitaxel-based regimens

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
disease control rate(DCR)	6 months

Collaborators and Investigators

• Sponsor: Fujian Cancer Hospital

Publications and helpful links

General Publications

• Zhao S, Fan N, Li H, Liu J, Huang F, Chen Y, Zhou M, Yu J, Lin R. Apatinib combined with paclitaxel-based chemotherapy in patients with taxane-resistant advanced gastric cancer: a single-arm exploratory study. Ann Transl Med. 2020 Oct;8(19):1233. doi: 10.21037/atm-20-5841.

Study record dates

Study Major Dates

• Study Start (Actual): August 1, 2016
• Primary Completion (Actual): March 31, 2018
• Study Completion (Anticipated): October 31, 2018

Study Registration Dates

• First Submitted: February 25, 2016
• First Submitted That Met QC Criteria: February 28, 2016
• First Posted (Estimate): March 3, 2016

Study Record Updates

• Last Update Posted (Actual): October 17, 2018
• Last Update Submitted That Met QC Criteria: October 13, 2018
• Last Verified: October 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Stomach Diseases; Neoplasms; Stomach Neoplasms; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Phytogenic; Protein Kinase Inhibitors; Paclitaxel; Apatinib
• Other Study ID Numbers: AHEAD-G323

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED